<DOC>
	<DOCNO>NCT01389661</DOCNO>
	<brief_summary>This trial pretend validate clinical use bioengineered product compose MSV cell ( mesenchymal stem cell produce IBGM , Valladolid , already approve Spanish Regulatory Agency three previous clinical trial ) cross-linked matrix autologous plasma patent The Blood Tissue Bank Asturias ( WO2008/ 119855 ) bone maxillary cyst refill . These two group collaborate present project team Maxillofacial Surgery Hospital Universitario del Río Hortega , lead clinical trial deal medical aspect . The propose trial base positive result obtain previous animal study perform present multidisciplinary team . The investigator propose phase I / II clinical trial 10 patient suffer bone cysts maxillofacial region . Autologous mesenchymal stem cell isolate bone marrow sample seed autologous plasma matrix cultivate 3 week . At time , cyst remove surgery cavity fill protein matrix contain mesenchymal cell . Checks conduct 3 week , 3 6 month follow evolution cavity panoramic radiography computerize tomography scan .</brief_summary>
	<brief_title>Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells ( MSV-H )</brief_title>
	<detailed_description>The objective project provide competitive clinical solution autologous product , balance cost possibility extend use pathology . This protocol include treatment 10 patient cystic disease jaw meet inclusion criterion none exclusion criterion . For autologous cell preparation sample spongy bone maxillary tuberosity 20 ml serum obtain patient order prepare crosslinked protein matrix MSV-H cell . Cells select expanded GMP condition accord methodology use previous trial ( EudraCT 2005-005498-36 , 2008-001191-68 2009-0170450-11 ) . MSV-H cell obtain directly biopsy culture jawbone patient cultivation technique `` vitro '' differentiate 21 day convey matrix osteogenic differentiation medium follow composition : DMEM , 10 % FBS , 1 % P / E , 0.1 mM dexamethasone , 50 mM ascorbate 2-phosphate , 10 mM phosphate ßGlicerol . All differentiation factor already approve clinical use . After period product differentiation implant patient . The bioimplant use refill bone defect osteotomy maxillary cyst enucleation , 5-10 million cell per unit 2 cm diameter 0.3 cm thick . The cavity close mucoperiosteal flap suture reabsorbable material . The end point trial evaluate feasibility , safety indication treatment efficacy accord clinical criterion objective image confirm volumetric bone regeneration maintenance time . For purpose orthopantomography exploration perform 2 6 month intervention .</detailed_description>
	<criteria>Maxillar bone cyst diameter large 2 cm small 4 cm Understanding write acceptance assay condition Informed write consent patient assay surgery In woman , negative pregnancy test t=0 In woman , compromise use anticonceptive method study Age 18 65 Incapacity legal dependence Pregnancy , lactancy , enrollment fertility program Previous concomitant oncological process . Positive serology HIV1 orHIV2 , Hepatitis B ( HBsAg , AntiHCVAb ) Hepatitis C ( AntiHCVAb ) . Immunocompromised patient Systemic disease potential effect bone metabolism Congenital acquire maxillofacial malformation Patients prescription drug act bone metabolism , suc glucocorticoid bisphosphonates Active recent infection cyst Recidive cyst ( previous surgery ) Participation trial study last 3 month . Other pathologic condition circumstance difficult participation study accord medical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Maxillary bone cyst</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Autologous serum scaffold</keyword>
</DOC>